CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Ibritumomab Tiuxetan (Zevalin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00607854
NCT00607854Phase 2Completed
CompareCT.gov

Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.

University Hospital, Bordeaux·interventional·Posted Feb 6, 2008·Updated Oct 5, 2016

In Brief

A Phase 2 clinical trial evaluating Ibritumomab Tiuxetan (Zevalin) for Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. Completed, enrolled 31 participants across 12 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of Zevalin® in a Reduced Intensity Conditioning regimen followed by allogenic stem cell support in patients with aggressive lymphomas who are responsive to a salvage chemotherapy regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
CountriesFrance
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartFeb 1, 2008
Primary CompletionFeb 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.4 years ago

Interventions

Ibritumomab Tiuxetan (Zevalin)drug

Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation. Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)